Hydroxychloroquine / azithromycin in COVID-19: The association between time to treatment and case fatality rate

Autor: Lidia M. López, Grisel Jesús Ynga-Meléndez, Juan Diego Mendoza-Saldaña, Juan Alonso Leon-Abarca, Juan Carlos Madrid-Cisneros, Roberto A. Accinelli
Jazyk: angličtina
Rok vydání: 2021
Předmět:
vomiting
myalgia
Multivariate analysis
time to treatment
very elderly
diarrhea
rash
Azithromycin
Logistic regression
Hydroxychloroquine
(HCQ)
Coronavirus disease 2019
(COVID-19)
newborn
Peruvian
Peru
Case fatality rate
Medicine
pain
ageusia
Maternal-Infant Center
(MIC)
outpatient care
fever
child
case fatality rate
adult
primary medical care
chill
nausea
backache
sore throat
Mean Cytotoxic Concentration
(CC50%)
aged
comorbidity
female
Infectious Diseases
Mean Maximum Inhibitory Concentration
(MIC50%)
drug withdrawal
Drug Therapy
Combination
Female
headache
medicine.drug
Hydroxychloroquine
Adult
medicine.medical_specialty
Coronavirus disease 2019 (COVID-19)
Time to treatment
nose obstruction
Article
Time-to-Treatment
coronavirus disease 2019
male
Internal medicine
Humans
irritability
Selectivity Index
(SI)
human
arthralgia
decreased appetite
Mortality
coughing
dizziness
unspecified side effect
business.industry
SARS-CoV-2
abdominal pain
thorax pain
Public Health
Environmental and Occupational Health
COVID-19
dyspnea
medicine.disease
infant
major clinical study
Comorbidity
clinical feature
COVID-19 Drug Treatment
eye redness
Severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2)
Oxygen Saturation
disease duration
business
Angiotensin converting enzyme 2
(ACE2)
body temperature
anosmia
Azithromycin
(AZIT)
Mean Effective Concentration
(EC50)
Zdroj: Travel Medicine and Infectious Disease
ISSN: 1873-0442
1477-8939
Popis: Background Currently, there is no formally accepted pharmacological treatment for COVID-19. Materials and methods We included COVID-19 outpatients of a Peruvian primary care center from Lima, Peru, who were treated between April 30 - September 30, 2020, with hydroxychloroquine and azithromycin. Logistic regression was applied to determine factors associated with case-fatality rate. Results A total of 1265 COVID-19 patients with an average age of 44.5 years were studied. Women represented 50.1% of patients, with an overall 5.9 symptom days, SpO2 97%, temperature of 37.3 °C, 41% with at least one comorbidity and 96.1% one symptom or sign. No patient treated within the first 72 h of illness died. The factors associated with higher case fatality rate were age (OR = 1.06; 95% CI 1.01–1.11, p = 0.021), SpO2 (OR = 0.87; 95% CI 0.79–0.96, p = 0.005) and treatment onset (OR = 1.16; 95% CI 1.06–1.27, p = 0.002), being the latter the only associated in the multivariate analysis (OR = 1.18; 95% CI 1.05–1.32, p = 0.005). 0.6% of our patients died. Conclusions The case fatality rate in COVID-19 outpatients treated with hydroxychloroquine/azithromycin was associated with the number of days of illness on which treatment was started.
Databáze: OpenAIRE
Externí odkaz: